肺抑瘤合剂联合AP化疗方案治疗非小细胞肺癌临床疗效观察  

Clinical Efficacy of Feiyiliu Mixture Combined with AP Chemotherapy Regimen in Treatment of Non-small Cell Lung Cancer

作　　者：刘思远[1] 李志鹏[2] 郑心[1] 

机构地区：[1]山东中医药大学,济南250355 [2]山东省立医院西院,济南250022

出　　处：《中国实验方剂学杂志》2018年第3期185-190,共6页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：山东省科技发展计划项目(2014GSF119015)

摘　　要：目的：观察肺抑瘤合剂联合AP（培美曲塞＋顺铂）化疗方案治疗非小细胞肺癌临床疗效及对细胞炎性因子的影响。方法：选择符合纳入标准的非小细胞肺癌患者62例,采用简单数字的随机方法分为对照组和治疗组,每组31例。两组均采用规范的西药治疗,对照组给予AP（培美曲塞＋顺铂）化疗方案,在此基础上给予复方斑蝥胶囊口服,3粒/次,2次/d。治疗组在AP（培美曲塞＋顺铂）方案基础上给予肺抑瘤合剂口服,每次100 m L,3次/d。观察两组患者治疗前后生活质量评分、临床证候积分、血清中细胞炎性因子白细胞介素（IL）-6,IL^（-1）7,前列腺素E2（PGE2）水平变化,以及治疗后两组间瘤体改善情况、不良事件发生率,统计临床疗效。结果：治疗组治疗后在生活质量评分、证候积分（咳嗽、咳血、胸痛、乏力、发热）、血清中细胞炎性因子（IL-6,IL^（-1）7,PGE2）水平较治疗前明显改善,且优于对照组（P〈0.05）;治疗组治疗后瘤体的稳定率明显优于对照组（P〈0.05）,且不良事件发生率低于对照组（P〈0.05）。结论：肺抑瘤合剂联合AP化疗方案能更有效地改善非小细胞肺癌患者生活质量、临床症状及实体瘤大小,降低细胞炎性因子在患者血清中的表达,降低临床不良事件的发生,值得进一步推广研究。Objective： To observe the clinical efficacy of Feiyiliu mixture and AP chemotherapy（pemetrexed ＋ cis-platinum） in the treatment of non-small cell lung cancer and its effect on inflammatory factors.Method： The 62 patients with non-small cell lung cancer who met the inclusion criteria were randomly divided into the control group and the treatment group,with 31 patients in each group. The control group was given AP chemotherapy regimen and compound cantharis capsule,3 pills/time,bid; the treatment group was orally given Feiyiliu mixture in addition of AP regimen,100 m L/time,tid. The changes in scores of quality of life,symptom scores,interleukin（IL）-6,IL^（-1）7,prostaglandin E2（PGE2） solid tumor after treatment,and incidence of adverse events were observed in two groups before and after treatment,and the clinical efficacy was evaluated.Result： The treatment group＇s scores of quality of life,integral syndrome（cough,hemoptysis,chest pain,fatigue and fever） and cytokines（IL-6,IL^（-1）7,PGE2） after treatment were significantly lower than those of control group（P〈0. 05）; the rate of tumor stability after treatment was significantly better than that of control group（P〈0. 05）; the incidence of adverse events was lower than that of control group（P〈0. 05）. Conclusion： Feiyiliu mixture combined with AP chemotherapy can effectively improve quality of life,clinical symptoms and tumor size in patients with non-small cell lung cancer,and decrease the expressions of inflammatory cytokines in serum of the patients,and is worth further promotion.

关 键 词：肺抑瘤合剂 AP方案 非小细胞肺癌 白细胞介素-6(IL-6) 白细胞介素-17(IL-17) 前列腺素E2(PGE2) 

分 类 号：R22[医药卫生—中医基础理论] R24[医药卫生—中医学]